NeuroOne Medical Technologies Corporation
NMTC · Price history
Price at last available close
$0.85
−$0.45 (-34.62%) 1M
2026-10-27
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About NeuroOne Medical Technologies Corporation
Primary reporting period: 2025-09-30 · Research updated Oct 13, 2026. A research update is not a new financial filing.
Who they are
NeuroOne Medical Technologies Corporation functions as a specialized medical technology enterprise. Its core mission involves the invention and market deployment of sophisticated thin-film electrode systems. These systems are crafted for diverse neurophysiological applications, such as the continuous recording of electroencephalograms (cEEG) and stereoelectroencephalograms (sEEG), as well as therapeutic interventions including spinal cord stimulation, brain stimulation, and ablation procedures.
How they make money
NeuroOne generates revenue primarily through the commercialization of its thin film electrode technology, including product sales and licensing agreements. The company earns income by selling diagnostic and therapeutic electrodes to hospitals and through milestone payments and royalties from strategic distribution partners like Zimmer Biomet.
Products & services
The company develops thin film electrode technology for EEG/sEEG recording, monitoring, and brain ablation, including the Evo Cortical and Evo sEEG electrodes and the OneRF Brain Ablation System.
Brands & revenue mix
Includes Evo Cortical and Evo sEEG electrode technologies.
Separate brand revenue is not available in this research.Source
Brain ablation system for neurological procedures.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer types
Disclosed major customers
- Zimmer BiometSource
Customer concentration
For the fiscal year ended September 30, 2025, Zimmer Biomet accounted for a significant portion of the company's total revenue through its distribution agreement.
Suppliers, materials & equipment
- Contract Manufacturers — The company relies on third-party contract manufacturers for the production of its electrode components and systems; specific supplier names are not disclosed.Source
Business relationships & partnerships
- Zimmer Biomet — A strategic distribution and licensing agreement for the commercialization of the company's Evo Cortical, Evo sEEG, and OneRF Brain Ablation System.Source
Competitors
Strengths
Sources
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
26
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
27
Poor
Financial Strength
8
Business Quality / Moat
54
Management
40
Growth Quality
8
Risk / Durability
13
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
28
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
40/100
Building Historical Record
Model Score 40/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.
The model outlook is currently cautious.
- •Asset quality scores strongly
- •Recent buyback activity is present
- •Material dilution — approximately 50.0% share-count growth
- •Debt service risk
- •M&A headline · Aug 18, 2026
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
Company-specific research
Questions worth answering for NMTC
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •What is driving NMTC's revenue decline, and does the latest company filing suggest the weakness is temporary or structural?
- •How long can NMTC fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •How is NMTC likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
- •What specifically needs to improve for NMTC to reach sustainable profitability?
- •What future growth or profitability would be needed to justify NMTC's current valuation?
Essential Investment Snapshot
Wall Street Score
26
Opportunity Score
28
Market Cap
$7.7M
P/E Ratio
-1.2
EPS
$-0.91
52-Week High
$6.54
52-Week Low
$0.96
Beta
0.64
Analyst Target
$5.00
Shares Outstanding
6.7M
Total Revenue
$10.0M
Total Debt
$73K
Dividend
No current dividend
Liquidation Value / Share
$0.56
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Strong downward momentum
High movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for NMTC
Detected from reported data — verify before acting.Material dilution — approximately 50.0% share-count growth
Diluted shares outstanding grew ~50.0% year-over-year. Substantial dilution reduces per-share value and can signal financing stress. Wall Street Score is capped.
Historical repurchase activity
Reported cash flows or share-count measures indicate past repurchase activity. This does not verify an active buyback authorization or future purchases.
Debt service risk
Interest coverage is low (~-12.7x). Earnings may be strained to cover interest expense.
M&A headline · Aug 18, 2026
$6 Million in New Markets Tax Credit Financing for the Acquisition, Renovation, and Equipping of a Tractor Assembly Facility in Monroeville, AL — This is a provider-linked headline, not an independently confirmed event. Check the article and company filings for the subject, proposed/completed status, and subsequent updates.
GuruFocusCommunity Sentiment
0 active · 0 total callsNo personal call yet on NMTC.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +FDA 510(k) cleared thin film electrode technology.
- +Strategic distribution partnership with Zimmer Biomet.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Medical - Devices industry.
- −History of operating losses and dependence on additional financing.
- −Reliance on a limited number of third-party manufacturers.
- −Negative free cash flow may increase the need for outside financing and dilution.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
3 historical score records availablePrevious Score
26
Oct 1, 2026
Change
-0.1
points
Current Score
26
Oct 8, 2026
Category Changes
NMTC decreased 0.1 points because some fundamentals weakened.
Projected Score
Projected Score
25
Projected Change
-0.4 points
Preliminary comparable-period financial changes suggest decline of approximately 0.4 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
Valuation unavailableCurrent Price
$0.85
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Large reported revenue change: +250.4%
Revenue changed sharply from 2024 to 2025. This can reflect a real business change, acquisition, divestiture, discontinued operations, restatement, or reporting-basis change. Compare the underlying filing before treating it as normal growth or decline.
TTM may combine quarters from before and after the event, so its trend can also be distorted.
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $13.0M | $12.1M | $3.5M | $2.0M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $4.4M | $4.0M | $2.4M | $1.5M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $8.6M | $8.1M | $1.1M | $457K | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $5.4M | $5.0M | $5.1M | $6.9M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $7.8M | $7.4M | $7.9M | $6.9M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $16.2M | $12.4M | $13.0M | $12.4M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | -$6.9M | -$3.0M | -$11.8M | -$11.7M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | -$7.6M | -$4.2M | -$11.9M | -$12.0M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $0.00 | $334K | $229K | $0.00 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | -$7.1M | -$3.6M | -$12.3M | -$11.9M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | -$7.1M | -$3.6M | -$12.3M | -$11.9M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $-0.91 | $-0.54 | $-2.76 | $-3.90 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 8.66M | 6.69M | 4.46M | 3.02M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 8.74M | 6.69M | 4.46M | 3.02M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$2.0M
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$0.23
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
-75.2%
Cash Change
-74.5%
Margin Change
-13.2 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Debt reduced
What Weakened
- Margins contracted
- Cash position declined
Potential Score Impact
Positive indicators included revenue growth, EPS growth, debt levels. Pressure indicators included cash levels, net income margin. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue increased 16.3%. EPS increased 24.1%. Cash declined 74.5%. Total debt declined 75.2%. Net income margin declined by 13.2 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
3 historical recordsHistorical Score Chart
3 of 3 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
Medical - DevicesNews
NeuroOne (NASDAQ: NMTC) secures a $4.5M order as revenue climbs again
NeuroOne Reports Preliminary Fiscal Q4 Product Revenue Growth of 38.4%; Secures Record $4.5 Million Purchase Order
Innovative Eyewear (NASDAQ:LUCY) and NeuroOne Medical Technologies (NASDAQ:NMTC) Head-To-Head Review
$10 Million in New Markets Tax Credit Financing for a New cold Storage and Refrigerated Logistics Facility in Albertville, AL
Rumor Mill · NMTC
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial